10 Best Immunology Stocks To Buy Now

8. SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

Number of Hedge Fund Holders: 40

SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) is dedicated to developing targeted therapies for rare diseases and cancer. The company focuses on high unmet medical needs and its key products include OGSIVEO (nirogacestat) for desmoid tumors and GOMEKLITM (mirdametinib) for neurofibromatosis type 1 with plexiform neurofibromas (NF1-PN).

SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) is advancing nirogacestat, a gamma-secretase inhibitor, as a BCMA potentiator for immunotherapy in multiple myeloma. The drug is being evaluated in combination with various BCMA-targeted therapies, including antibody-drug conjugates, CAR T cell therapies, bispecific antibodies, and monoclonal antibodies, to enhance treatment efficacy, making it one of the leading best immunology stocks in the world.

SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) has established key research collaborations to explore nirogacestat’s immunological potential. It is partnering with Fred Hutchinson Cancer Research Center to study its role in BCMA modulation and with Dana-Farber Cancer Institute to evaluate its effects using preclinical multiple myeloma models. These efforts highlight the company’s commitment to advancing targeted therapies for improved cancer treatment.

SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)’s OGSIVEO’s net product revenue in Q3 2024 was $49.3 million, a 23% sequential increase. Demand from both new and returning patients who saw clinical advantages drove this expansion. Due to its successful debut, OGSIVEO is now the accepted systemic treatment for desmoid tumors. Given that only a small percentage of eligible patients have been contacted thus far, market research suggests substantial growth potential. Patient convenience and adherence have increased with the introduction of new tablet strengths and blister packaging.